Expectations and Concerns Towards New Extended Half-Life (EHL) Products - Results of Surveys Among Haemophilia Patients from the Dach Region

被引：0
|
作者：
von Mackensen, Sylvia [1 ]
Kalnins, Werner [2 ]
Lino, Hostettler [3 ]
Joerg, Krucker [3 ]
Albisetti, Manuela [4 ,5 ]
Weiss, Josef [6 ]
Pabinger, Ingrid [7 ]
Oldenburg, Johannes [8 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Inst Med Psychol, Hamburg-Eppendorf, Germany
[2] German Haemophilia Soc DHG, Hamburg, Germany
[3] Swiss Hemophilia Assoc SHG, Altstatten, Switzerland
[4] Swiss Hemophilia Network SHN, Zurich, Switzerland
[5] Univ Childrens Hosp, Dept Hematol, Zurich, Switzerland
[6] Austrian Hemophilia Soc OHG, Vienna, Austria
[7] Med Univ Vienna, Dept Med I, Vienna, Austria
[8] Univ Clin Bonn, Inst Expt Haematol & Transfus Med, Bonn, Germany
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 46 条
  • [41] SAFETY AND EFFICACY OF N9-GP, A RECOMBINANT GLYCOPEGYLATED FACTOR IX WITH EXTENDED HALF-LIFE, IN US VS GLOBAL PATIENTS WITH HEMOPHILIA B: RESULTS FROM THE PARADIGM™ CLINICAL PROGRAM
    Young, Guy
    Lentz, Steven R.
    Kearney, Susan
    Escobar, Miguel
    Seremetis, Stephanie
    Cooper, David
    Walsh, Christopher
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (09) : E75 - E75
  • [42] Interim results from a phase I/II study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN)
    Choudhury, N.
    Jain, P.
    Dowlati, A.
    Thompson, J.
    Johnson, M. L.
    Mamdani, H.
    Sanborn, R. E.
    Schenk, E. L.
    Aggarwal, R.
    Sankar, K.
    Walker, L. N.
    Anand, B.
    Beltran, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S486 - S486
  • [43] Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).
    Beltran, Himisha
    Dowlati, Afshin
    Jain, Prantesh
    Johnson, Melissa Lynne
    Sanborn, Rachel E.
    Thompson, Jonathan Robert
    Mamdani, Hirva
    Schenk, Erin L.
    Aggarwal, Rahul Raj
    Sankar, Kamya
    Gramza, Ann W.
    Anand, Banmeet S.
    Choudhury, Noura J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 121 - 121
  • [44] Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    Subklewe, Marion y
    Stein, Anthony
    Walter, Roland B.
    Bhatia, Ravi
    Wei, Andrew H.
    Ritchie, David
    Bucklein, Veit
    Vachhani, Pankit
    Dai, Tian
    Hindoyan, Antreas
    Agarwal, Suresh
    Anderson, Abraham
    Khaldoyanidi, Sophia
    Ravandi, Farhad
    BLOOD, 2019, 134
  • [45] Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC)
    Beltran, Himisha
    Johnson, Melissa Lynne
    Jain, Prantesh
    Schenk, Erin L.
    Sanborn, Rachel E.
    Thompson, Jonathan Robert
    Dowlati, Afshin
    Mamdani, Hirva
    Aggarwal, Rahul Raj
    Anand, Banmeet S.
    Gramza, Ann W.
    Choudhury, Noura J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study
    Minocha, Mukul
    Thompson, Corbin G.
    Murphy, Alexis
    Zhou, Yanchen
    Brandl, Christian
    Parkes, Amanda
    Chen, Xi
    Yu, Brian
    Martinez, Pablo
    Houk, Brett E.
    CLINICAL PHARMACOKINETICS, 2024, 63 (12) : 1757 - 1768
12345